Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-02-13
DOI
10.1038/srep42499
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure
- (2015) Alessandro Granito et al. DIGESTIVE AND LIVER DISEASE
- Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib
- (2015) Andrea Casadei Gardini et al. EXPERT OPINION ON PHARMACOTHERAPY
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials
- (2014) Gemma Cramarossa et al. Biomarkers in Medicine
- Drug Therapy for Advanced-Stage Liver Cancer
- (2014) Markus Peck-Radosavljevic Liver Cancer
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
- (2013) Yu-Yun Shao et al. JOURNAL OF HEPATOLOGY
- Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study
- (2013) G. Brandi et al. ONCOLOGIST
- Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
- (2012) R-D Hofheinz et al. BRITISH JOURNAL OF CANCER
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Why Does Every Hepatocellular Carcinoma Clinical Trial Using Molecular Targeted Agents Fail?
- (2012) Liver Cancer
- Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
- (2011) S Stintzing et al. BRITISH JOURNAL OF CANCER
- Adjuvant Therapy With Capecitabine Postpones Recurrence of Hepatocellular Carcinoma After Curative Resection: A Randomized Controlled Trial
- (2010) Yong Xia et al. ANNALS OF SURGICAL ONCOLOGY
- Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options
- (2010) Luca Faloppi et al. CANCER TREATMENT REVIEWS
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Maximum tolerated dose: clinical endpoint for a bygone era?
- (2009) Chris H. Takimoto Targeted Oncology
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: A retrospective analysis
- (2007) Jae-Lyun Lee et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started